Andrew S. Ittleman/LinkedIn
Nov 5, 2025, 05:27
Andrew S. Ittleman: Florida’s New Stem Cell Laws Raise FDA and Patient Safety Concerns
Andrew S. Ittleman, Owner at Fuerst Ittleman David & Joseph, shared on LinkedIn:
”In July, Florida passed new “stem cell therapy” laws, which allow physicians to administer allogeneic “stem cell” products to patients. Among other problems with Florida’s new stem cell laws, they (i) authorize products which FDA prohibits, (ii) do not define “stem cell,” (iii) create a risk of patient confusion.
We have decades of history to understand the potential consequences of these laws, but that history seems to have been ignored during the legislative process. I explore these issues in the article available at the link below.”
Find more information here.
Stay informed with Hemostasis Today.
-
Oct 14, 2026, 11:58Cesare Medri: A New Learning Achievement in Haemoglobin Disorder Care
-
Oct 14, 2026, 07:36Daniel Pereira Monteiro: ASCAT 2026 A Day of Science, Connection and Community
-
Oct 14, 2026, 07:20Rachael Jackman: Understanding Models of Transfusion Medicine at AABB 2026
-
Oct 14, 2026, 07:09Dianne E. van der Wal: A New Chapter in Academia Celebrating a Journey in Research, Teaching and Platelet Science
-
Oct 14, 2026, 06:55Mahdieh Dagina Pedersen: A Meaningful Milestone in Hemophilia A Research and Oral Drug Development
-
Oct 14, 2026, 06:37Neoklis Mparis: Unilateral Adrenal Haemorrhage in Primary Antiphospholipid Syndrome During Bridging Anticoagulation
-
Oct 14, 2026, 06:00Aymen A.: LAAC vs. OAC in Patients with Atrial Fibrillation Including CHAMPION-AF and CLOSURE-AF Trials
-
Oct 13, 2026, 21:05Francisco Chacón-Lozsán: Heparin-Induced Thrombocytopenia – When an Anticoagulant Triggers Thrombosis
-
Oct 13, 2026, 21:04Aref Zribi: Isolated Tumor Thrombus and the Role of Prophylactic Anticoagulation